Opill enhances access to oral contraception.

UNINTENDED PREGNANCY among adolescents remains an ongoing concern. Amjad and colleagues note limited access to reliable contraception, inconsistent use of birth control, stigma, and lack of comprehensive sex education as barriers to preventing unintended pregnancy. Among these factors, according to Amjad and colleagues, inconsistent or incorrect use of contraception is the primary cause, underscoring the need for better education and access to effective methods. (See Unintended pregnancy: Facts and figures.)

Opill, the first over-the-counter (OTC) oral contraceptive approved by the U.S. Food and Drug Administration (FDA), has the potential to address some of these challenges, and nurses have a critical role to play in providing counseling, education, and facilitating access. According to Wong and colleagues, nurse-led contraceptive counseling programs can increase consistent and correct use of birth control and improve reproductive health outcomes among adolescents. Allen and colleagues and Shiroff emphasize that by increasing awareness and education about this accessible contraceptive option, nurses and other providers can help reduce barriers to contraception, promote proper use, and ultimately contribute to lowering unintended pregnancy rates among this vulnerable population.

What is Opill?

Norgestrel, a synthetic progestin that combines active levonorgestrel and inactive dextronorgestrel, has been used for many years as an effective contraceptive. Originally approved by the FDA in 1973 as a prescription drug, norgestrel marked a significant milestone in 2023 when it returned to the market under the brand name Opill as an OTC contraceptive in the United States.

By removing barriers associated with prescription options—healthcare visits and associated costs as well as privacy and stigma concerns—Opill has the potential to reduce the number of unintended pregnancies, especially among teenagers.

Allowing individuals to obtain Opill directly from pharmacies without a prescription, beginning contraception becomes easier and faster, especially in time-sensitive situations (for example, after unprotected sex, contraceptive failure, or when immediate access is needed but scheduling a healthcare visit would cause delay). This increased accessibility can lead to more consistent and timely use.

The shift from prescription-only to OTC availability is one of the most significant changes in contraceptive access since the pill was first introduced. It represents a major step toward empowering individuals to take control of their reproductive health.

Mechanisms of action

Opill, a progestin-only pill (POP) with 0.075 mg of norgestrel, has multiple mechanisms of action. According to Glasier and colleagues, they include thickening cervical mucus, ovulation inhibition, and endometrial effects.

Thickening cervical mucus. The most important and lasting mechanism of action for POPs is their effect on cervical mucus. Research by Glasier and colleagues shows that these pills cause the cervical mucus to become thicker and more viscous, which creates an unfavorable environment for sperm penetration. This change occurs within a few hours after taking the pill and serves as the primary barrier to pregnancy.

Ovulation inhibition. Although this effect of POPs isn’t as strong as that of combined oral contraceptives (COCs), they can still suppress ovulation in some cycles. According to research by Glasier and colleagues, POPs inhibit ovulation in about 50% of cycles.

Endometrial effects. Opill’s alteration of the lining of the endometrium serves as a secondary mechanism of action. By changing the endometrial environment, progestin may reduce the likelihood of implantation if fertilization occurs.

POPs vs COCs

Recent research confirms POPs, like Opill, have a significantly different and more favorable safety profile than COCs, especially with regard to cardiovascular risks. According to Shapero and Madden, POPs are safe for most patients with coexisting cardiac conditions, unlike COCs which carry higher risks.

In addition, the traditional justification for prescription-only status based on screening for conditions like hypertension and diabetes is more relevant for COCs than POPs. Grossman and Kinsey confirm that the safety profile of POPs makes it an appropriate candidate for OTC status. (See Comparative safety profile.)

Timing and effectiveness

The contraceptive effect of Opill depends on consistent daily intake. Unlike COCs, POPs have a shorter window for effectiveness. Earlier clinical studies recommended taking the pill at approximately the same time each day, with a narrow margin of error of about 3 hours. According to a recent clinical trial by Tran and colleagues, the perfect-use effectiveness rate reaches 98%, meaning only 2 out of 100 women would experience an unintended pregnancy during a year of use. Perfect use demands strict adherence to the regimen: taking one tablet daily at the same time without interruption between monthly packs. Research shows that this level of effectiveness depends on consistent timing and adequate backup contraception in the event of missed doses or delays of more than 3 hours.

The real-use effectiveness rate is notably lower compared to perfect use. Recent research (including by Allen and Bartz and the FDA) suggests that Opill’s real-use failure rate is about 7% to 8% during the first year. In other words, about seven to eight out of every 100 women who use the pill under typical conditions will become pregnant within a year. When considering all users, including those who stop, Glasier and colleagues and Chabbert-Buffet and colleagues have reported real-use pregnancy rates as high as 17.8%

Several key factors contribute to the difference between perfect- and real-use effectiveness, including timing adherence, missed doses, and user characteristics (such as metabolism, body weight, medications, and consistency in taking the pill).

Timing adherence. Recent research has provided reassuring data about timing flexibility. A 2023 randomized, crossover study by Glasier and colleagues found that taking Opill up to 3 hours late or missing one pill had minimal effect on ovarian activity or cervical mucus and may not significantly impact contraceptive efficacy. However, optimal effectiveness still requires consistent daily use.

Missed doses. Research by Chabbert-Buffet and colleagues indicates the flexibility of Opill, but completely skipping a dose will reduce Opill’s effectiveness at preventing pregnancy.

User characteristics. Smith and colleagues and Ott and colleagues found that effectiveness rates vary by age (younger users typically have higher failure rates), experience with oral contraceptives, access to healthcare support and education, and life circumstances that might affect daily medication routines.

Weight and Opill efficacy

The relationship between body weight and contraceptive failure rates remains unclear and can vary depending on the type of contraceptive method used. According to a comprehensive review by Shapero and Madden, some studies suggest that oral contraceptive failure rates measure slightly higher among users with a body mass index (BMI) over 30. However, the overall evidence shows that hormonal contraceptive methods remain highly effective across different weight groups. This finding reassures both healthcare providers and patients about the reliability of these methods, regardless of body weight.

Specifically for contraceptive pills containing only levonorgestrel, a comprehensive 2023 review by Hammad and colleagues found that, although theoretical concerns exist about reduced efficacy in obese women, clinical data indicate that modern COCs with levonorgestrel remain reliably effective across all BMI groups. In real-world settings, according to Hamad and colleagues, no significant difference exists in failure rates based on body weight.

Contraindications

For norgestrel, contraindications include known or suspected pregnancy and unexplained vaginal bleeding. According to the Centers for Disease Control and Prevention’s Medical Eligibility Criteria for Contraceptive Use, active breast cancer represents the sole Category 4 contraindication (an unacceptable health risk) for POPs. Norgestrel also is contraindicated in patients with suspected breast carcinoma or other progestin-sensitive cancers, as well as those with a personal history of these conditions. In addition, individuals with acute hepatic disease or benign or malignant liver tumors shouldn’t use the medication. Contraindication extends to those with hypersensitivity to norgestrel or any components of the drug formulation, including tartrazine.

Implications for practice

When considering Opill as a contraceptive option, providers must conduct thorough screening and patient education to ensure safe and effective use. Before recommending Opill, rule out pregnancy through careful history-taking and pregnancy testing when indicated. Although initiation of norgestrel can occur at any point in the menstrual cycle, confirmation of non-pregnant status is essential for proper counseling and timing. Providers should identify and screen for contraindications to POPs, including current breast cancer, severe liver disease, and unexplained vaginal bleeding.

Opill is particularly appropriate for adolescents who have contraindications to estrogen-containing contraceptives; require a highly effective, reversible contraceptive method; can commit to taking the medication at approximately the same time each day; and have no contraindications to POPs.

Patient education

Patient education about Opill should cover several key points, including the importance of taking the pill at approximately the same time each day, as its contraceptive effect on cervical mucus is quickly reversible. Advise patients that if they miss a pill, or if vomiting or severe diarrhea occurs within 4 hours of taking the pill, they should take another pill as soon as possible to ensure adequate absorption. According to Glasier and colleagues, no significant risks exist for taking an extra pill in these circumstances. However, if the patient misses more than one pill or absorption is repeatedly affected, they should use a backup contraceptive method, such as condoms, for the next 48 hours.

Research by Chabbert-Buffet and colleagues indicates that delayed or missed doses may compromise contraceptive efficacy, necessitating the use of a backup nonhormonal contraceptive method for 48 hours after the missed dose. Explain to the patient that they’ll require pregnancy testing in the event of delayed menstruation after missing a pill or if they suspect that they’re pregnant.

Provide the patient with information regarding common side effects, including irregular bleeding patterns, so they know what to expect and don’t become unnecessarily concerned. Also inform them about the rapid onset of contraceptive protection through cervical mucus changes, as this both explains the mechanism of action and reassures patients who may be attentive to physical changes after starting the pill. (See What patients should know.)

Initiation and follow-up care

The CDC’s Selected Practice Recommendations for Contraceptive Use (SPR) confirm that physical examinations and laboratory tests aren’t required before beginning POPs. This evidence-based guideline supports the safe and effective use of these medications without prerequisite medical screening.

Regular follow-up care helps to ensure the proper use of Opill and address concerns promptly. Results of a study by Laurora and colleagues indicate the importance of proper follow up for maintaining contraceptive efficacy.

During follow-up visits, review the importance of taking the pill at approximately the same time each day, discuss challenges with maintaining the dosing schedule, and address barriers to consistent use. In addition, provide strategies for remembering daily doses, such as setting phone reminders or linking pill-taking to daily routines.

To encourage follow-up among adolescents and young adults, consider using tailored communication strategies that emphasize confidentiality, accessibility, and convenience. Smith and colleagues note that text message reminders, mobile health apps, and flexible scheduling can improve follow-up rates in patients between ages 15 and 25. Building trust through nonjudgmental counseling and providing education on the importance of follow-up care for both efficacy and side effect management also can encourage continued engagement. Peer support programs and integrating contraceptive follow-up into routine adolescent health visits can further enhance adherence and retention.

Assess Opill side effects and bleeding patterns. Tran and colleagues recommend that healthcare providers systematically evaluate patients for changes in menstrual bleeding patterns, the presence and severity of any side effects, and the impact of side effects on daily activities and quality of life. In addition, ask about any new symptoms since starting the medication.

Remind patients that irregular bleeding patterns are common during the first few months of use and frequently stabilize over time. Suggest documenting bleeding patterns to help identify any concerning trends that require further evaluation.

Evaluate ongoing contraceptive needs. During follow-up visits, assess patient satisfaction with Opill, review any changes in reproductive goals, and discuss alternative contraceptive options as needed. In addition, evaluate whether norgestrel remains the most appropriate choice based on the patient’s current health status and preferences.

Screen for new contraindications. Regular screening should include updates to the patient’s medical history, blood pressure monitoring, cardiovascular risk factor assessment, and evaluation of new medications that might interact with norgestrel. Also screen for new conditions that might affect hormonal contraception safety, such as migraine with aura, newly diagnosed hypertension, venous thromboembolism, liver disease, or changes in smoking status for patients over age 35.

Recommended follow-up schedule. Initial follow-up typically occurs after 3 months of use, with subsequent visits scheduled annually or more frequently if concerns arise. Patients with specific medical conditions, such as hypertension, diabetes, a history of thromboembolic disorders, liver disease, or migraine with aura, or those experiencing side effects may require more frequent monitoring.

Barriers to Opill access

Despite the FDA approval of OTC Opill, longstanding barriers to equitable contraceptive access persist. Nurses can work to identify these barriers and implement strategies that help patients overcome them.

Financing and provider knowledge. Many successful outreach programs that provide contraceptive services face inconsistent or short-term funding, making it difficult to maintain services and provide follow-up. According to Johnson and colleagues, federal funding for contraceptive services remains fragmented and inadequate, which affects the sustainability of these programs.

The study also found that many patients have difficulty finding providers with up-to-date knowledge about new contraceptive options, including OTC pills. Addressing these knowledge gaps and funding limitations will improve access and outcomes. Nurses can help by staying current on the latest contraceptive guidelines through continuing education, proactively sharing new information about OTC options with patients during clinic visits, and advocating for in-service training sessions or resource updates within their healthcare settings.

Disparities. According to findings from the 2024 Kaiser Family Foundation Women’s Health Survey, awareness of Opill and other OTC options remains low, with only 26% of women ages 18 to 49 reporting awareness. According to Frederiksen and colleagues, this indicates a significant lack of knowledge about this option, particularly among younger women, Hispanic women, and those with lower incomes or less education.

Cost also remains a significant barrier, particularly for uninsured women. In fact, one in five uninsured women (20%) reported having to stop using a birth control method because they couldn’t afford it. Those living in states with restrictive reproductive health policies also are less likely to access or consistently use OTC pills. Nurses can help by connecting patients to available financial assistance programs, sliding scale clinics, or community resources that offer low- or no-cost contraception. They also can educate patients about generic or lower-cost options and advocate for expanded access to affordable reproductive health services within their communities and healthcare organizations.

Policy and community interventions. At the policy level, the FDA’s approval of OTC Opill serves as a significant step. Community-level interventions, on the other hand, might include local health departments launching public awareness campaigns about OTC contraceptive options, clinics partnering with schools or community centers to provide education sessions, or nonprofit organizations distributing informational materials and free samples at community events. These initiatives work directly within communities to increase knowledge, reduce stigma, and improve access to contraception.

Although patients can now acquire Opill without a prescription, the Kaiser Family Foundation notes that expanding pharmacist prescribing authority continues to play an important role in increasing access to contraception, lowering costs, and enhancing patient safety through direct consultation and guidance. Some states, including Oregon, California, and Colorado, have considered or enacted policies to expand pharmacist prescribing authority or remove age restrictions, which can further improve access. According to Long and colleagues, these state-level initiatives are vital for increasing contraceptive availability.

Additionally, emerging federal proposals, as outlined by the Centers for Medicare & Medicaid Services, require insurers to cover OTC contraceptives without cost-sharing or prescription requirements. This will help reduce financial obstacles that hinder individuals from obtaining their chosen contraceptive methods.

Expanding access

Several models, including community health worker (CHW) programs, culturally specific outreach, mobile clinics, and peer navigation, have shown promise in increasing contraceptive uptake, especially in underserved populations. Sharma and colleagues note the effectiveness of CHWs in bridging gaps in knowledge, trust, and service delivery, which can make contraceptive access more equitable and responsive to local needs.

Evidence from Sharma and colleagues suggests that these scalable and cost-effective models can be integrated with current OTC contraceptive options, such as Opill, as well as future OTC oral contraceptives, to reach adolescents and marginalized groups more effectively.

Programs tailored to adolescents include school-based health centers, peer educators, and confidential, youth-friendly services. These models improve knowledge and reduce stigma. Ott and colleagues note that the American Academy of Pediatrics recommends developmentally appropriate contraceptive counseling and emphasizes protecting adolescent confidentiality. Human-centered design approaches and community partnerships support the development of navigator programs for adolescent contraception.

Current peer-reviewed studies, including research by Steiner and colleagues, highlight the critical role of targeted outreach in improving contraceptive uptake. Effective strategies—such as pharmacy-based counseling, youth-focused programs, and digital health platforms—help connect adolescents, especially those hesitant to seek in-person care, with the contraception resources they need. These approaches not only increase awareness but also reduce barriers, making contraception more accessible and acceptable to diverse youth populations.

Nurse expertise and commitment

The approval of Opill as the first OTC oral contraceptive marks an important shift in reproductive healthcare. It provides a safe, effective, and accessible contraceptive option for most people, especially adolescents and those who can’t use estrogen-based methods. Nurses can help identify barriers to access and advocate for solutions that support equitable contraceptive care.

Ultimately, nurses can empower patients by providing clear guidance, addressing concerns, and staying updated on new contraceptive options. This expanded access serves as a meaningful step forward, but its impact depends on nurses’ expertise and commitment to patient-centered education and support.

Maryam Ghobadzadeh is an associate professor and assistant director of the BSN program at National University in Fresno, California.

References

Allen RH, Bartz D. Opill: The over-the-counter contraceptive pill. Obstet Gynecol. 2024;143(2):242-51. doi:10.1097/AOG.0000000000005455

Amjad S, MacDonald I, Chambers T, et al. Social determinants of health and adverse maternal and birth outcomes in adolescent pregnancies: A systematic review and meta­analysis. Paediatr Perinat Epidemiol. 2019;33(1):88-99. doi:10.1111/ppe.12529

Centers for Disease Control and Prevention. U.S. medical eligibility criteria for contraceptive use, 2024. MMWR Morb Mortal Wkly Rep. 2024;73(4):1-126.
Centers for Disease Control and Prevention. Unintended pregnancy. cdc.gov/reproductive-health/hcp/unintended-pregnancy/index.html

Chabbert-Buffet N, Jamin C, Lete I, et al. Missed pills: Frequency, reasons, consequences and solutions. Eur J Contracept Reprod Health Care. 2017;22(3)165-169. doi:10.1080/13625187.2017.1295437

Frederiksen B, Diep K, Salganicoff A. Contraceptive experiences, coverage, and preferences: Findings from the 2024 KFF Women’s Health Survey. Kaiser Family Foundation. November 22, 2024. kff.org/womens-health-policy/contraceptive-experiences-coverage-and-preferences-findings-from-the-2024-kff-womens-health-survey

Glasier A, Edelman A, Creinin MD, et al. The effect of deliberate non-adherence to a norgestrel progestin-only pill: A randomized, crossover study. Contraception. 2023;117:1-6. doi:10.1016/j.contraception.2022.09.002

Glasier A, Edelman A, Creinin MD, et al. Mechanism of action of norgestrel 0.075 mg a progestogen-only pill. I. Effect on ovarian activity. Contraception. 2022;112:37-42. doi:10.1016/j.contraception.2022.03.022

Glasier A, Sober S, Gasloli R, Goyal A, Laurora I. A review of the effectiveness of a progestogen-only pill containing norgestrel 75 µg/day. Contraception. 2022;105:1-6. doi:10.1016/j.contraception.2021.08.016

Grossman D, Kinsey ET. Over-the-counter oral contraceptives. JAMA. 2024;332(17):1478-9. doi: 10.1001/jama.2024.16474

Johnson PA, Brindis CD, Donelan K, et al. New directions for women’s health: Expanding understanding, improving research, addressing workforce limitations. Health Aff. 2025;44(2):156-62. doi:10.1377/hlthaff.2024.01004

Laurora I, Henrie B, Guillard H, Bradford R, Sober S, Goyal A. Evaluation of adherence to a daily progestin-only pill in a simulated over-the-counter setting. Contraception. 2024;133:110388. doi:10.1016/j.contraception.2024.110388

Long M, Diep K, Sobel L, Salganicoff A. Over-the-counter oral contraceptive pills. Kaiser Family Foundation. September 27, 2024. kff.org/affordable-care-act/issue-brief/over-the-counter-oral-contraceptive-pills

Ott MA, Hoopes AJ, Sucato GS, Leroy-Melamed M. Contraception for adolescents: Policy statement. Pediatrics. 2025;156(1):e2025072217. doi:10.1542/peds.2025-072217

Sharma MK, Das E, Sahni H, et al. Engaging community health workers to enhance modern contraceptive uptake among young first-time parents in five cities of Uttar Pradesh. Glob Health Sci Pract. 2024;12(suppl 2):e2200170. doi:10.9745/GHSP-D-22-00170

Shapero K, Madden T. The 2024 US medical eligibility criteria for contraceptive use: Application to practice in the care of patients with cardiac disease. Circ Res. 2025;126(3):e45-58. doi:10.1161/CIRCRESAHA.125.325682

Shiroff J. Norgestrel (Opill) is the first over-the-counter oral contraceptive pill approved in the United States. Nurs Womens Health. 2024;28(2)148-51. doi:10.1016/j.nwh.2024.01.002

Steiner RJ, Axelson SM, Nuñez-Eddy C, et al. Knowledge gaps and information needs and preferences regarding oral contraceptive pills and over-the-counter access: A focus group study with Black and Latinx young people assigned female at birth. Contraception. 2025;147:110900. doi:10.1016/j.contraception.2025.110900

Tran G, Wollen J, Davis S, Wang EM, Arriazola J, Rosario N. A review of recommendations, efficacy, and patient safety for over-the-counter norgestrel for daily contraception. Explor Res Clin Soc Pharm. 2025;18:100591. doi:10.1016/j.rcsop.2025.100591

U.S. Food and Drug Administration. Opill (0.075 mg oral norgestrel tablet) information. January 16, 2024. fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/opill-0075mg-oral-norgestrel-tablet-information

Wong J, Arefadib N, Botfield JR, Rilloraza, Mazza D. Nurse and midwife interventions to improve access to contraception and abortion in primary care: A systematic review. BMJ Sex Reprod Health. 2026;16:bmjsrh-2025-202716. doi: 10.1136/bmjsrh-2025-202716

American Nurse Journal. 2026; 21(4). Doi: 10.51256/ANJ042631

Key words: Opill, contraception, over-the-counter contraception